Skip to main content
Top
Published in: Clinical Rheumatology 4/2021

01-04-2021 | Systemic Sclerosis | Brief Report

How do patients define Raynaud’s phenomenon? Differences between primary and secondary disease

Authors: Susan L. Murphy, Alain Lescoat, Mary Alore, Michael Hughes, John D. Pauling, Maya Sabbagh, Dinesh Khanna

Published in: Clinical Rheumatology | Issue 4/2021

Login to get access

Abstract

Introduction/objectives

To examine how people define Raynaud’s phenomenon (RP) based on their lived experiences and explore if differences exist depending on primary or secondary RP diagnosis.

Method

An international survey was sent to people with RP through health systems, foundations, and social media. Qualitative coding of responses to an open text question regarding one’s own definition of RP was performed and themes were identified. The prevalence of themes among the sample and then comparisons between themes among people who self-reported primary versus secondary diagnosis of RP were performed.

Results

There were 1345 respondents from 45 countries (mean age 51.5 years, 93% female) who defined RP in their own words; 17% reported primary RP and 83% reported secondary RP (69% of secondary RP was scleroderma-related, n = 927). Over half defined their RP by describing the body parts affected, color changes, pain, and triggers or situations in which an episode occurs. Patients with primary RP more frequently defined RP in terms of its impact on function/quality of life and pain compared to those with secondary RP (34.5% versus 25.3%, respectively, p=0.004; 54.0% versus 46.8%, p=0.05). Patients with secondary RP more frequently included specific body parts, color change, the management of attacks, and other digital vascular complications in their definition of RP.

Conclusions

We have identified differences in how people with primary and secondary RP define RP, in terms of how they feel and function. Our findings have implications for the domains of outcome measures for assessing RP within different patient populations.
Key Points
• Pain is more often mentioned in primary RP and color change in secondary RP.
• Over 25% of patients included reduced the quality of life as part of their RP definition.
• The concept of “attack” is used to define RP by only 2% of patients.
Literature
1.
go back to reference Wigley F, Flavahan N (2016) Raynaud’s phenomenon. N Engl J Med. 375(6):556–565CrossRef Wigley F, Flavahan N (2016) Raynaud’s phenomenon. N Engl J Med. 375(6):556–565CrossRef
2.
go back to reference Maricq H, Carpentier P, Weinrich M, Keil J, Franco A, Drouet P et al (1993) Geographic variation in the prevalence of Raynaud’s phenomenon: Charleston, SC, USA, vs Tarentaise, Savoie, France. J Rheumatol. 20(1):70–76PubMed Maricq H, Carpentier P, Weinrich M, Keil J, Franco A, Drouet P et al (1993) Geographic variation in the prevalence of Raynaud’s phenomenon: Charleston, SC, USA, vs Tarentaise, Savoie, France. J Rheumatol. 20(1):70–76PubMed
3.
go back to reference Hughes M, Khanna D, Pauling J (2020) Drug initiation and escalation strategies of vasodilator therapies for Raynaud’s phenomenon: Can we treat to target? Rheumatology (Oxford). 59(3):464–466CrossRef Hughes M, Khanna D, Pauling J (2020) Drug initiation and escalation strategies of vasodilator therapies for Raynaud’s phenomenon: Can we treat to target? Rheumatology (Oxford). 59(3):464–466CrossRef
4.
go back to reference Pauling J, Hughes M, Pope J (2019) Raynaud’s phenomenon—an update on diagnosis, classification and management. Clin Rheumatol. 38(12):3317–3330CrossRef Pauling J, Hughes M, Pope J (2019) Raynaud’s phenomenon—an update on diagnosis, classification and management. Clin Rheumatol. 38(12):3317–3330CrossRef
5.
go back to reference Pauling JD, Domsic RT, Saketkoo LA, Almeida C, Withey J, Jay H, Frech TM, Ingegnoli F, Dures E, Robson J, McHugh NJ, Herrick AL, Matucci-Cerinic M, Khanna D, Hewlett S (2018) Multinational qualitative research study exploring the patient experience of Raynaud’s phenomenon in systemic sclerosis. Arthritis Care Res. 70(9):1373–1384CrossRef Pauling JD, Domsic RT, Saketkoo LA, Almeida C, Withey J, Jay H, Frech TM, Ingegnoli F, Dures E, Robson J, McHugh NJ, Herrick AL, Matucci-Cerinic M, Khanna D, Hewlett S (2018) Multinational qualitative research study exploring the patient experience of Raynaud’s phenomenon in systemic sclerosis. Arthritis Care Res. 70(9):1373–1384CrossRef
6.
go back to reference Denton C, Khanna D (2017) Systemic sclerosis. Lancet. 390(10103):1685–1699CrossRef Denton C, Khanna D (2017) Systemic sclerosis. Lancet. 390(10103):1685–1699CrossRef
7.
go back to reference Maricq H, Carpentier P, Weinrich M, Keil J, Palesch Y, Biro C, Vionnet-Fuasset M, Jiguet M, Valter I (1997) Geographic variation in the prevalence of Raynaud’s phenomenon: a 5 region comparison. J Rheumatol. 24(5):879–889PubMed Maricq H, Carpentier P, Weinrich M, Keil J, Palesch Y, Biro C, Vionnet-Fuasset M, Jiguet M, Valter I (1997) Geographic variation in the prevalence of Raynaud’s phenomenon: a 5 region comparison. J Rheumatol. 24(5):879–889PubMed
8.
go back to reference Pauling J, Saketkoo L, Matucci-Cerinic M, Ingegnoli F, Khanna D (2018) The patient experience of Raynaud’s phenomenon in systemic sclerosis. Rheumatology (Oxford). 58(1):18–26CrossRef Pauling J, Saketkoo L, Matucci-Cerinic M, Ingegnoli F, Khanna D (2018) The patient experience of Raynaud’s phenomenon in systemic sclerosis. Rheumatology (Oxford). 58(1):18–26CrossRef
9.
10.
go back to reference Hughes M, Pauling JD, Jones J, Denton CP, Domsic RT, Frech TM, Herrick AL, Khanna D, Matucci-Cerinic M, McKenzie L, Saketkoo LA, Gooberman-Hill R, Moore A (2020) Patient experiences of digital ulcer development and evolution in systemic sclerosis. Rheumatology (Oxford). 59(8):2156–2158CrossRef Hughes M, Pauling JD, Jones J, Denton CP, Domsic RT, Frech TM, Herrick AL, Khanna D, Matucci-Cerinic M, McKenzie L, Saketkoo LA, Gooberman-Hill R, Moore A (2020) Patient experiences of digital ulcer development and evolution in systemic sclerosis. Rheumatology (Oxford). 59(8):2156–2158CrossRef
11.
go back to reference Lescoat A, Coiffier G, de Carlan M, Droitcourt C, Ballerie A, Cazalets C, Perdriger A, Jégo P (2018) Combination of capillaroscopic and ultrasonographic evaluations in systemic sclerosis: results of a cross-sectional study. Arthritis Care Res. 70(6):938–943CrossRef Lescoat A, Coiffier G, de Carlan M, Droitcourt C, Ballerie A, Cazalets C, Perdriger A, Jégo P (2018) Combination of capillaroscopic and ultrasonographic evaluations in systemic sclerosis: results of a cross-sectional study. Arthritis Care Res. 70(6):938–943CrossRef
12.
go back to reference Lescoat A, Yelnik CM, Coiffier G, Wargny M, Lamotte C, Cazalets C, Belhomme N, Ballerie A, Hatron PY, Launay D, Perdriger A, Sobanski V, Hachulla E, Jégo P (2019) Ulnar artery occlusion and severity markers of vasculopathy in systemic sclerosis: a multicenter cross-sectional study. Arthritis Rheumatol. 71(6):983–990CrossRef Lescoat A, Yelnik CM, Coiffier G, Wargny M, Lamotte C, Cazalets C, Belhomme N, Ballerie A, Hatron PY, Launay D, Perdriger A, Sobanski V, Hachulla E, Jégo P (2019) Ulnar artery occlusion and severity markers of vasculopathy in systemic sclerosis: a multicenter cross-sectional study. Arthritis Rheumatol. 71(6):983–990CrossRef
13.
go back to reference Hachulla E, Hatron PY, Carpentier P, Agard C, Chatelus E, Jego P, Mouthon L, Queyrel V, Fauchais AL, Michon-Pasturel U, Jaussaud R, Mathian A, Granel B, Diot E, Farge-Bancel D, Mekinian A, Avouac J, Desmurs-Clavel H, Clerson P, SEDUCE study group (2016) Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Ann Rheum Dis. 75(6):1009–1015CrossRef Hachulla E, Hatron PY, Carpentier P, Agard C, Chatelus E, Jego P, Mouthon L, Queyrel V, Fauchais AL, Michon-Pasturel U, Jaussaud R, Mathian A, Granel B, Diot E, Farge-Bancel D, Mekinian A, Avouac J, Desmurs-Clavel H, Clerson P, SEDUCE study group (2016) Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Ann Rheum Dis. 75(6):1009–1015CrossRef
14.
go back to reference Denton CP, Hachulla É, Riemekasten G, Schwarting A, Frenoux JM, Frey A, le Brun FO, Herrick AL, on behalf of the Raynaud Study Investigators (2017) Efficacy and safety of selexipag in adults with Raynaud’s phenomenon secondary to systemic sclerosis: a randomized, placebo-controlled, phase II study. Arthritis Rheumatol. 69(12):2370–2379CrossRef Denton CP, Hachulla É, Riemekasten G, Schwarting A, Frenoux JM, Frey A, le Brun FO, Herrick AL, on behalf of the Raynaud Study Investigators (2017) Efficacy and safety of selexipag in adults with Raynaud’s phenomenon secondary to systemic sclerosis: a randomized, placebo-controlled, phase II study. Arthritis Rheumatol. 69(12):2370–2379CrossRef
15.
go back to reference Pauling JD, Saketkoo LA, Domsic RT (2018) Patient perceptions of the Raynaud’s condition score diary provide insight into its performance in clinical trials of Raynaud’s phenomenon: comment on the article by Denton et al. Arthritis Rheumatol. 70(6):973–974CrossRef Pauling JD, Saketkoo LA, Domsic RT (2018) Patient perceptions of the Raynaud’s condition score diary provide insight into its performance in clinical trials of Raynaud’s phenomenon: comment on the article by Denton et al. Arthritis Rheumatol. 70(6):973–974CrossRef
Metadata
Title
How do patients define Raynaud’s phenomenon? Differences between primary and secondary disease
Authors
Susan L. Murphy
Alain Lescoat
Mary Alore
Michael Hughes
John D. Pauling
Maya Sabbagh
Dinesh Khanna
Publication date
01-04-2021
Publisher
Springer International Publishing
Published in
Clinical Rheumatology / Issue 4/2021
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-021-05598-7

Other articles of this Issue 4/2021

Clinical Rheumatology 4/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.